Intervacc AB is a Swedish company
active in Life Science. To meet the increasing demands of effective vaccines in animal health
Intervacc develops new vaccines based on recombinant proteins.
The technology platform is based on research
at the Karolinska Institute and the Swedish University of Agricultural Sciences. The focus is primarily on the development of its first vaccine candidate, Strangvac ®, which is a vaccine against strangles caused by Streptococcus equi. Strangvac ® has shown good documented protective effect against a disease that presently lacks a safe and
Intervacc is a public company with more than 180 shareholders
. The research team along with Nordvacc Läkemedel, Knutsson Holdings and Lyftet Holdings represent the major shareholders.